REMARKS

Claim 51 has been rejected under 35 U.S.C.§103(a) as unpatentable over Goldberg et al., WO 99/18986 in view of the article by Reff et al. (Critical Review of Oncology/Hematology).

The Examiner's rejection is respectfully traversed.

The Examiner has previously indicated that claims 55 and 56 are allowable. As claim 51 has now been amended to be dependent on claims 55 or 56, this claim should also be allowable.

In view of the foregoing, it is believed that the amended claims and the claims dependent there from are in proper form. The Applicants respectfully contend that the teachings of Goldberg et al., WO 99/18986 in view of the article by Reff et al. (Critical Review of Oncology/Hematology) do not establish *prima facie* case of obviousness under the provisions of 35 USC §103(a). Thus, Claims 51 and 55-56 are considered to be patentably distinguishable over the prior art of record.

The application is now considered to be in condition for allowance, and an early indication of same is earnestly solicited.

The Commissioner is authorized to charge Deposit Order Account No. 19-0079 for any fees that may be required.

Respectfully submitted,



Arlene J. Powers
Registration No. 35,985
Gauthier & Connors LLP
225 Franklin Street, Suite 3300
Boston, Massachusetts 02110
Telephone: (617) 426-9180
Extension 110